RNS Number : 2941F
Arecor Therapeutics PLC
21 May 2026
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
GRANT OF OPTIONS AND PDMR DEALING
Cambridge, UK, 21 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, announces that on 20 May 2026 (the "Grant Date") the Company granted a total of 455,000 options under the Company's Long Term Incentive Plan ("LTIP Options") over new ordinary shares of 1 pence each in the Company ("Ordinary Shares").
Details of options granted to PDMRs are included in the table below.
Name of individual
Job title
Number of LTIP Options granted under 2026 award
Price (£)
Sarah Howell
Chief Executive Officer
160,000
0.01
David Ellam
Chief Financial Officer
105,000
0.01
Jan Jezek
Chief Scientific Officer
95,000
0.01
David Gerring
Chief Development Officer
95,000
0.01
The LTIP Options have an exercise price of 1 pence. Performance conditions include both time (30% of the options granted) and Share Price Outperformance* (70% of the options granted) during the three-year performance period. The LTIP Options are subject to continued service and the extent to which the performance conditions are satisfied. Vesting does not occur until the end of the three-year performance period. Vested LTIP Options will normally be exercisable from after the end of the three-year performance period and until the tenth anniversary of the Grant Date, after which time they will lapse if not exercised. They are subject to a condition that the LTIP Options or the Ordinary Shares acquired on exercise of the LTIP Options (other than those sold to cover tax and National Insurance) are held for a minimum one-year period from vesting.
*Outperformance when compared to the FTSE AIM All Share index.
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc Dr Sarah Howell, Chief Executive Officer David Ellam, Chief Financial Officer
+44 (0) 1223 426060 info@arecor.com
Singer Capital Markets Advisory LLP (NOMAD and Broker)
+44 (0) 20 7496 3000
Phil Davies, James Fischer
Vigo Consulting (Financial Communications)Melanie Toyne-Sewell, Rozi Morris
+44 (0) 20 7390 0230 arecor@vigoconsulting.com
Vida Strategic Partners (US Investor Relations) Stephanie Diaz
+1 (415) 675-7401 sdiaz@vidasp.com
Notes to Editors
Arecor Therapeutics plc is a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.
Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin, which enables disruptive drug delivery devices. It is being co-developed with Sequel Med Tech, a company commercialising state-of-the art insulin delivery devices. Arecor is also developing a novel oral delivery platform for peptides with its first validation target a GLP-1 receptor agonist.
The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com
Arecor® and Arestat® are registered trademarks of Arecor Limited.
About AT278
AT278 is a novel proprietary formulation of an existing insulin, designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). With its best-in-class profile, it has the potential to disrupt the market for insulin treatment as the first concentrated, yet very rapid-acting-insulin for the growing population of people with diabetes with high daily insulin needs as well as to act as a critical enabler in the development of next-generation, miniaturised longer wear automated insulin delivery (AID) systems.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely associated
a)
Name:
1. Sarah Howell 2. David Ellam 3. Jan Jezek 4. David Gerring
2.
Reason for the notification
a)
Position/status:
1. Chief Executive Officer and Executive Director 2. Chief Financial Officer and Executive Director 3. Chief Scientific Officer 4. Chief Development Officer
b)
Initial notification/Amendment:
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name:
Arecor Therapeutics plc
b)
LEI:
98450093D12I3A8DDD58
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument: Identification code:
Ordinary shares of 1 pence each GB00BMWLM973
b)
Nature of the transaction:
Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHAKDBNCBKKQPB
